Author/Authors :
Lemos، نويسنده , , Pedro A. and Arampatzis، نويسنده , , Chourmouzios A and Saia، نويسنده , , Francesco and Hoye، نويسنده , , Angela and Degertekin، نويسنده , , Muzaffer and Tanabe، نويسنده , , Kengo and Lee، نويسنده , , Chi-Hang and Cummins، نويسنده , , Paul C. Smits، نويسنده , , Pieter C and McFadden، نويسنده , , Eugene and Sianos، نويسنده , , Georgios and de Feyter، نويسنده , , Pim and van Der ، نويسنده ,
Abstract :
A total of 91 patients with 112 lesions received 2.25-mm sirolimus-eluting stents (SESs), and these lesions were compared with those treated with SESs of ≥2.5-mm diameter in the same procedure (n = 109). The reference diameters were 1.88 ± 0.34 and 2.52 ± 0.57 mm, respectively (p <0.01). At follow-up, the late lumen loss was 0.07 ± 0.48 mm for the 2.25-mm SES versus 0.03 ± 0.38 mm for the larger SES (p = 0.5), and the binary restenosis rate was 10.7% versus 3.9%, respectively (p = 0.1). The 12-month target lesion revascularization rate was 5.5%. In conclusion, 2.25-mm SESs were associated with low rates of clinical and angiographic late complications.
